ACHV - Achieve Life Sciences Inc

NYSE * Health Care * Biotechnology

$5.58

$-0.25 (-4.29%)

About Achieve Life Sciences Inc

Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.

ACHV Key Statistics

Market Cap

$310.35M

0

P/B Ratio

9.23

EPS

$-1.35

Employees

25

How ACHV Compares to Peers

ACHV is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

N/A

of 5

Size Rank

#6

of 6

CompanyP/EGrowthCompare
ACHVN/A0%-
AMGN25.60%vs AMGN
GILD19.30%vs GILD
VRTX31.10%vs VRTX
REGN17.60%vs REGN
BIIB15.00%vs BIIB

Achieve Life Sciences Inc Company Information

Headquarters
Washington; U.S.A
Website
www.achievelifesciences.com
Sector
Health Care
Industry
Biotechnology
Data Updated:
Ready to invest in ACHV?

Commission-free trading available. Affiliate links.

ACHV Lician Score

5% confidence
4.0/10
Neutral

ACHV has a Lician Score of 4/10 (Average). Areas of concern: Growth.

value

5.0

growth

2.0

quality

5.0

momentum

5.0

safety

5.0

The Lician Score is a comprehensive 1-10 rating that evaluates ACHVacross five key dimensions: Value (valuation relative to sector),Growth (revenue and earnings trajectory),Quality (profitability and balance sheet strength),Momentum (price trends and analyst sentiment), andSafety (volatility and risk metrics).

ACHV Financial Snowflake

5-axis analysis across key investment dimensions

4.4/10

Neutral

35810Value5.0Growth2.0Quality5.0Momentum5.0Safety5.04.4/10
5.0

Value

2.0

Growth

5.0

Quality

5.0

Momentum

5.0

Safety

Upcoming Events for ACHV